Helio Genomics has expanded the commercial reach of its blood-based HelioLiver test for early liver cancer detection through a new partnership with Syneos Health, aiming to speed up adoption across the healthcare landscape.
Helio Genomics has expanded the commercial reach of its blood-based HelioLiver test for early liver cancer detection through a new partnership with Syneos Health, aiming to speed up adoption across the healthcare landscape.
Helio Genomics has struck a deal with Syneos Health to widen the commercial push for HelioLiver, its blood-based test for the early detection of hepatocellular carcinoma, the company said on Tuesday. The financial terms were not disclosed.
The agreement adds another distribution and sales channel for the Irvine, California-based diagnostics group, which has been steadily building access to the assay through outside partners. In 2021, Helio forged a commercial and co-branding arrangement with Fulgent Genetics, and earlier this year it began making the test available to providers linked to Quest Diagnostics.
HelioLiver uses artificial intelligence methods to analyse cell-free DNA methylation patterns, protein biomarkers and patient demographics in an effort to identify liver cancer earlier than conventional approaches. The company has also been supported by clinical and promotional claims from partners. Fulgent said in 2021 that late-breaking data showed the test outperformed alpha-fetoprotein and the GALAD model, while a later study published in the Journal of Hepatology reported better sensitivity than ultrasound in patients with cirrhosis.
Bharat Tewarie, Helio Genomics’ chief executive, said in a statement that partnering with Syneos Health marks a significant step in the company’s commercial strategy and should speed up engagement with healthcare providers nationwide. Syneos Health, a major life sciences services group, brings established commercial infrastructure that Helio is now using to expand awareness of the test beyond its existing partnerships.
The broader effort comes as liver cancer screening remains a difficult and important clinical area, with companies racing to promote blood-based tools that may complement or improve on imaging. Helio’s latest move suggests it is leaning on partners not just for distribution, but also for the sales execution needed to move a niche oncology test into wider routine use.
About Helio Genomics
Helio Genomics is a commercial-stage, AI-driven TechBio company revolutionizing diagnostics for early cancer detection and minimal residual disease monitoring. Its advanced multi-analyte blood-based platform harnesses machine learning and deep learning to detect cancer biomarkers, enabling clinicians and patients to respond decisively against cancer.
For more information about Helio Genomics and HelioLiver™, visit www.heliogenomics.com.
Media Contact: Danielle Fox, (360) 509-9527
About HelioLiver™
HelioLiver™ is a blood-based test for early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer. It combines cell-free DNA methylation patterns, protein biomarkers, and patient demographics using a proprietary AI algorithm. In the CLiMB trial — the world's first prospective, blinded, multicenter U.S. study for HCC screening, enrolling nearly 1,968 patients across approximately 50 major clinical sites — HelioLiver demonstrated 4x greater sensitivity for Stage I liver cancer compared to ultrasound, surpassing all FDA-specified endpoints.2,3 This simple blood draw addresses screening barriers, boosting early detection rates, and improving outcomes for individuals with risk factors for liver cancer, including liver cirrhosis (from Hepatitis B/C, alcohol use, obesity, or MASLD). Clinically validated in multicenter studies involving thousands of patients, Helio Genomics is expanding its commercial footprint to combat this pressing health challenge.
About Syneos Health
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, commercial and real world insights into outcomes to address modern market realities.
We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share diverse insights, use the latest technologies and apply advanced business practices to speed our customers' delivery of important therapies to patients.
Syneos Health is powered by an authentic, inclusive and high-performance culture that cares for colleagues, customers, patients, communities and the environment.
Learn more about how our expert team members can help accelerate your success. Visit syneoshealth.com.
References
- Barriers to Surveillance for Hepatocellular Carcinoma in Multicenter Cohort
- DDW — CLiMB: A prospective, blinded, multicenter US based study evaluating a multi-analyte blood-based test for detecting HCC in patients with liver cirrhosis
- AGA — CLiMB: A prospective, blinded, multicenter US based study evaluating a multi-analyte blood-based test for detecting hepatocellular carcinoma (HCC) in patients with liver cirrhosis
- American Cancer Society Report — Liver Cancer, Fastest-Growing Cause of Cancer Death in the U.S.
- UpToDate.com: Clinical features and diagnosis of HCC
- Independence Blue Cross — Independence helps to get more at-risk members screened for liver cancer
View source version on noah-news.com